Bruker, Vermillion, Sigma-Aldrich, MorphoSys, SynGene | GenomeWeb
Bruker BioSpin Acquisition Completed; BioSciences Reports Profits Up 44 Percent in Q4
The purchase of Bruker BioSpin by Bruker BioSciences has been completed, resulting in the formation of a new company called Bruker, the company said this week.
About 57.5 million new unregistered shares of Bruker’s common stock were issued for the stock component of the deal. At a closing price of $10.86 per share on Feb. 25, the stock portion of the acquisition was approximately $624.9 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.